Kallelse till årsstämma i Infant Bacterial Therapeutics
April 05, 2022 14:00 ET
|
Infant Bacterial Therapeutics AB
Aktieägarna i Infant Bacterial Therapeutics AB (publ) kallas till årsstämma onsdagen den 4 maj 2022. Mot bakgrund av coronaviruset genomförs årsstämman genom förhandsröstning med stöd av tillfälliga...
Notice to attend the Annual General Meeting of Infant Bacterial Therapeutics
April 05, 2022 14:00 ET
|
Infant Bacterial Therapeutics AB
Shareholders of Infant Bacterial Therapeutics AB (publ) are summoned to the Annual General Meeting on Wednesday, May 4, 2022. In light of the coronavirus, the Annual General Meeting is conducted...
Infant Bacterial Therapeutics publicerar årsredovisning för 2021
March 31, 2022 02:00 ET
|
Infant Bacterial Therapeutics AB
Pressmeddelande 31 mars 2022 Infant Bacterial Therapeutics AB (publ) publicerar idag årsredovisningen för räkenskapsåret 2021. Årsredovisningen finns tillgänglig på IBTs hemsida,...
Infant Bacterial Therapeutics publishes Annual Report for 2021
March 31, 2022 02:00 ET
|
Infant Bacterial Therapeutics AB
Press release March 31, 2022 Infant Bacterial Therapeutics AB (publ) publishes today the Annual Report for 2021. The report is available on IBT’s website ibtherapeutics.com under the section...
Ultrasound AI’s Preterm AI Receives Its First Patent on International Women’s Day
March 28, 2022 12:00 ET
|
Ultrasound AI
HIGHLANDS RANCH, Colo., March 28, 2022 (GLOBE NEWSWIRE) -- Ultrasound AI™, Inc., an artificial intelligence company dedicated to improving women’s health, today announces that they were awarded...
Infant Bacterial Therapeutics AB (publ), (IBT) bokslutskommuniké 1 januari – 31 december 2021
February 04, 2022 14:00 ET
|
Infant Bacterial Therapeutics AB
Pressmeddelande den 4 februari, 2022 VD kommenterar IBT:s pågående avgörande fas III-studie syftar till att ta fram data som förbättrar prematura spädbarns möjligheter att överleva. Det görs genom...
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – December 31, 2021
February 04, 2022 14:00 ET
|
Infant Bacterial Therapeutics AB
Press release February 4, 2022 Message from the CEO IBT’s ongoing pivotal phase lll clinical trial aims to generate data to improve survival possibilities of premature infants. This is...
The Connection Study fortsätter efter planerad säkerhetsanalys av Data Monitoring Committee (DMC)
January 19, 2022 17:30 ET
|
Infant Bacterial Therapeutics AB
Den 30 september, 2021 meddelade Infant Bacterial Therapeutics (IBT) att företaget nått en viktig milstolpe i utvecklingen av IBP-9414, efter att ha rekryterat 600 för tidigt födda barn till The...
The Connection Study continues after pre-scheduled Data Monitoring Committee (DMC) review
January 19, 2022 17:30 ET
|
Infant Bacterial Therapeutics AB
On September 30, 2021 Infant Bacterial Therapeutics (IBT) announced that the company had reached a key milestone in the development of IBP-9414, after having recruited 600 premature infants to The...
Infant Bacterial Therapeutics tillkännager idag att ett nytt patent har godkänts i Australien
January 10, 2022 16:30 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (IBT) meddelar idag att patentverket i Australien utfärdat ett godkännande för patentet: “A method of activating lactic acid bacteria”, vilket omfattar formuleringar...